Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia

Ryan K. Shields, M. Hong Nguyen, Brian A. Potoski, Ellen G. Press, Liang Chen, Barry N. Kreiswirth, Lloyd G. Clarke, Gregory A. Eschenauer, Cornelius J. Clancy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Treatment failures of a carbapenem-colistin regimen among patients with bacteremia due to sequence type 258 (ST258), KPC-2-producing Klebsiella pneumoniae were significantly more likely if both agents were inactive in vitro, as defined by a colistin MIC of>2 μg/ml and the presence of either a major ompK36 porin mutation (guanine and alanine insertions at amino acids 134 and 135 [ins aa 134-135 GD], IS5 promoter insertion [P=0.007]) or a doripenem MIC of>8 μg/ml (P=0.01). Major ompK36 mutations among KPC-K. pneumoniae strains are important determinants of carbapenem-colistin responses in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)1797-1801
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

doripenem
Colistin
Porins
Carbapenems
Klebsiella pneumoniae
Bacteremia
Genotype
Mutation
Guanine
Treatment Failure
Alanine
Therapeutics
Amino Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology

Cite this

Shields, Ryan K. ; Nguyen, M. Hong ; Potoski, Brian A. ; Press, Ellen G. ; Chen, Liang ; Kreiswirth, Barry N. ; Clarke, Lloyd G. ; Eschenauer, Gregory A. ; Clancy, Cornelius J. / Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. In: Antimicrobial agents and chemotherapy. 2015 ; Vol. 59, No. 3. pp. 1797-1801.
@article{3239b7f74c0947b3a3358ff39586f16e,
title = "Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia",
abstract = "Treatment failures of a carbapenem-colistin regimen among patients with bacteremia due to sequence type 258 (ST258), KPC-2-producing Klebsiella pneumoniae were significantly more likely if both agents were inactive in vitro, as defined by a colistin MIC of>2 μg/ml and the presence of either a major ompK36 porin mutation (guanine and alanine insertions at amino acids 134 and 135 [ins aa 134-135 GD], IS5 promoter insertion [P=0.007]) or a doripenem MIC of>8 μg/ml (P=0.01). Major ompK36 mutations among KPC-K. pneumoniae strains are important determinants of carbapenem-colistin responses in vitro and in vivo.",
author = "Shields, {Ryan K.} and Nguyen, {M. Hong} and Potoski, {Brian A.} and Press, {Ellen G.} and Liang Chen and Kreiswirth, {Barry N.} and Clarke, {Lloyd G.} and Eschenauer, {Gregory A.} and Clancy, {Cornelius J.}",
year = "2015",
month = "3",
day = "1",
doi = "https://doi.org/10.1128/AAC.03894-14",
language = "English (US)",
volume = "59",
pages = "1797--1801",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. / Shields, Ryan K.; Nguyen, M. Hong; Potoski, Brian A.; Press, Ellen G.; Chen, Liang; Kreiswirth, Barry N.; Clarke, Lloyd G.; Eschenauer, Gregory A.; Clancy, Cornelius J.

In: Antimicrobial agents and chemotherapy, Vol. 59, No. 3, 01.03.2015, p. 1797-1801.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia

AU - Shields, Ryan K.

AU - Nguyen, M. Hong

AU - Potoski, Brian A.

AU - Press, Ellen G.

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Clarke, Lloyd G.

AU - Eschenauer, Gregory A.

AU - Clancy, Cornelius J.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Treatment failures of a carbapenem-colistin regimen among patients with bacteremia due to sequence type 258 (ST258), KPC-2-producing Klebsiella pneumoniae were significantly more likely if both agents were inactive in vitro, as defined by a colistin MIC of>2 μg/ml and the presence of either a major ompK36 porin mutation (guanine and alanine insertions at amino acids 134 and 135 [ins aa 134-135 GD], IS5 promoter insertion [P=0.007]) or a doripenem MIC of>8 μg/ml (P=0.01). Major ompK36 mutations among KPC-K. pneumoniae strains are important determinants of carbapenem-colistin responses in vitro and in vivo.

AB - Treatment failures of a carbapenem-colistin regimen among patients with bacteremia due to sequence type 258 (ST258), KPC-2-producing Klebsiella pneumoniae were significantly more likely if both agents were inactive in vitro, as defined by a colistin MIC of>2 μg/ml and the presence of either a major ompK36 porin mutation (guanine and alanine insertions at amino acids 134 and 135 [ins aa 134-135 GD], IS5 promoter insertion [P=0.007]) or a doripenem MIC of>8 μg/ml (P=0.01). Major ompK36 mutations among KPC-K. pneumoniae strains are important determinants of carbapenem-colistin responses in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84923240004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923240004&partnerID=8YFLogxK

U2 - https://doi.org/10.1128/AAC.03894-14

DO - https://doi.org/10.1128/AAC.03894-14

M3 - Article

VL - 59

SP - 1797

EP - 1801

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -